"In vitro systems to characterize the immune response to HIV-1 and HIV-1 vaccine candidates", NIAID Workshop Report, Bethesda, August 4, 2010

Vaccine

Volumn 29, Issue 29-30, 2011, Pages 4647-4653

  Malaspina, Angela ^a   Rinaldo, Charles R ^b   Sekaly, Rafick P ^c   Flores, Jorge ^d   D'Souza, Patricia M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c Vaccine and Gene Therapy Institute Florida (VGTI FL)   (United States)

^d Vaccine Development Global Program PATH   (United States)

Author keywords

HIV; In vitro; Model systems; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; CD40 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 1BETA; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; SUPPRESSOR OF CYTOKINE SIGNALING 1; YELLOW FEVER VACCINE;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; ADENOVIRUS; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; EXPLANT; HIGH THROUGHPUT SCREENING; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INFLUENZA VACCINATION; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROENVIRONMENT; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; SYSTEMS BIOLOGY; T LYMPHOCYTE; VIRUS REPLICATION;

EID: 79960644423     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.035     Document Type: Conference Paper

References (39)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392(6673):245-52.
2. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
3. Ueno H, Palucka AK, Banchereau J. The expanding family of dendritic cell subsets. Nat Biotechnol 2010;28(8):813-5.
4. Medzhitov R, Janeway Jr CA. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997;91(3):295-8.
5. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001;194(6):769-79.
6. Pulendran B, Palucka K, Banchereau J. Sensing pathogens and tuning immune responses. Science 2001;293(5528):253-6.
7. + T cell lines from naive precursors. Eur J Immunol 1995;25(5):1206-11.
8. + T lymphocyte responses in vitro using dendritic cells. J Immunol 1999;162(9):5197-204.
9. Schlienger K, Craighead N, Lee KP, Levine BL, June CH. Efficient priming of protein antigen-specific human CD4(+) T cells by monocyte-derived dendritic cells. Blood 2000;96(10):3490-8.
10. Itano AA, Jenkins MK. Antigen presentation to naive CD4 T cells in the lymph node. Nat Immunol 2003;4(8):733-9.
11. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001;106(3):263-6.
12. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008;205(13):3119-31.
13. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009;10(1):116-25.
14. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010;327(5963):291-5.
15. Sabado RL, Babcock E, Kavanagh DG, Tjomsland V, Walker BD, Lifson JD, et al. Pathways utilized by dendritic cells for binding, uptake, processing and presentation of antigens derived from HIV-1. Eur J Immunol 2007;37(7):1752-63.
16. + T-cell responses induced by myeloid dendritic cells. J Virol 2009;83(12):6288-99.
17. Lubong Sabado R, Kavanagh DG, Kaufmann DE, Fru K, Babcock E, Rosenberg E, et al. In vitro priming recapitulates in vivo HIV-1 specific T cell responses, revealing rapid loss of virus reactive CD4 T cells in acute HIV-1 infection. PLoS One 2009;4(1):e4256.
18. Niu L, Termini JM, Kanagavelu SK, Gupta S, Rolland MM, Kulkarni V, et al. Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes. Vaccine 2011;29(11):2110-9.
19. + T cells by targeting antigens to human dendritic cells through DCIR. Blood 2010;116(10):1685-97.
20. Subramanya S, Armant M, Salkowitz JR, Nyakeriga AM, Haridas V, Hasan M, et al. Enhanced induction of HIV-specific cytotoxic T lymphocytes by dendritic cell-targeted delivery of SOCS-1 siRNA. Mol Ther 2010;18(11):2028-37.
21. Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, Thompson-Snipes L, et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008;29(3):497-510.
22. + dendritic cells. J Exp Med 2010;207(6):1273-81.
23. + dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010;207(6):1247-60.
24. + dendritic cells. J Exp Med 2010;207(6):1261-71.
25. Higbee RG, Byers AM, Dhir V, Drake D, Fahlenkamp HG, Gangur J, et al. An immunologic model for rapid vaccine assessment - a clinical trial in a test tube. Altern Lab Anim 2009;37(Suppl. 1):19-27.
26. Ma Y, Poisson L, Sanchez-Schmitz G, Pawar S, Qu C, Randolph GJ, et al. Assessing the immunopotency of Toll-like receptor agonists in an in vitro tissue-engineered immunological model. Immunology 2010;130(3):374-87.
27. Byers AM, Tapia TM, Sassano ER, Wittman V. In vitro antibody response to tetanus in the MIMIC system is a representative measure of vaccine immunogenicity. Biologicals 2009;37(3):148-51.
28. Kahl CA, Bonnell J, Hiriyanna S, Fultz M, Nyberg-Hoffman C, Chen P, et al. Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. Vaccine 2010;28(35):5691-702.
29. Mastelic B, Ahmed S, Egan WM, Del Giudice G, Golding H, Gust I, et al. Mode of action of adjuvants: implications for vaccine safety and design. Biologicals 2010;38(5):594-601.
30. Lazaro E, Godfrey SB, Stamegna P, Ogbechie T, Kerrigan C, Zhang M, et al. Differential HIV epitope processing in monocytes and CD4 T cells affects cytotoxic T lymphocyte recognition. J Infect Dis 2009;200(2):236-43.
31. + T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells. J Exp Med 2009;206(7):1525-34.
32. Newell EW, Klein LO, Yu W, Davis MM. Simultaneous detection of many T-cell specificities using combinatorial tetramer staining. Nat Methods 2009;6(7):497-9.
33. Giese C, Demmler CD, Ammer R, Hartmann S, Lubitz A, Miller L, et al. A human lymph node in vitro - challenges and progress. Artif Organs 2006;30(10): 803-8.
34. Story CM, Papa E, Hu CC, Ronan JL, Herlihy K, Ploegh HL, et al. Profiling antibody responses by multiparametric analysis of primary B cells. Proc Natl Acad Sci USA 2008;105(46):17902-7.
35. Grivel JC, Margolis L. Use of human tissue explants to study human infectious agents. Nat Protoc 2009;4(2):256-69.
36. Saba E, Grivel JC, Vanpouille C, Brichacek B, Fitzgerald W, Margolis L, et al. HIV-1 sexual transmission: early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model. Mucosal Immunol 2010;3(3):280-90.
37. Denton PW, Garcia JV. Novel humanized murine models for HIV research. Curr HIV/AIDS Rep 2009;6(1):13-9.
38. Wege AK, Melkus MW, Denton PW, Estes JD, Garcia JV. Functional and phenotypic characterization of the humanized BLT mouse model. Curr Top Microbiol Immunol 2008;324:149-65.
39. Brainard DM, Seung E, Frahm N, Cariappa A, Bailey CC, Hart WK, et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol 2009;83(14):7305-21.